Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jennifer L Johansen"'
Autor:
Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this mod
Externí odkaz:
https://doaj.org/article/a35e5923581b4b07b7b03b97b3b2d842
Autor:
Thomas Hutson, Peter Van Veldhuizen, Michael R Harrison, Scott S Tykodi, Daniel J George, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Ivor Percent, Rakesh Singal, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features
Externí odkaz:
https://doaj.org/article/2afaa38ab63544b783e82c3073c180bf
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47447a8d84cc5d3bc187e0281ee97bfe
https://doi.org/10.1002/cncr.34016
https://doi.org/10.1002/cncr.34016
Autor:
Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina, Jeff Yorio, Arash Rezazadeh Kalebasty, Heidi McKean, Nishan Tchekmedyian, Scott S Tykodi, Joshua Zhang, Margarita Askelson, Jennifer L Johansen, Thomas E Hutson
Publikováno v:
BMJ Open. 12:e058396
ObjectivesThe non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this modi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61f69c2a60ef790779f03ad7748425d
https://doi.org/10.1136/bmjopen-2021-058396
https://doi.org/10.1136/bmjopen-2021-058396
Autor:
Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Edward Arrowsmith, Todd M. Bauer, Rohit K. Jain, Bradley Somer, Elaine T. Lam, Mark D. Kochenderfer, Ana Molina, Gurjyot Doshi, Brian Lingerfelt, Ralph J. Hauke, Vijay Gunuganti, Ian Schnadig, Peter Van Veldhuizen, Mark Fleming, Robert Galamaga, Mukul Gupta, Hugo Hool, Thomas Hutson, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Scott S. Tykodi
Publikováno v:
Clinical genitourinary cancer. 18(6)
Background The open-label, phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab monotherapy 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e2375c7bc5ed92e4e42d211e83e78de
https://pubmed.ncbi.nlm.nih.gov/32718906
https://pubmed.ncbi.nlm.nih.gov/32718906
Autor:
Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Todd M. Bauer, Ana Molina, Ralph J. Hauke, James A. Reeves, Sunil Babu, Peter Van Veldhuizen, Bradley Somer, Vijay Gunuganti, Ian Schnadig, Saby George, Ray D. Page, Edward Arrowsmith, Rohit K. Jain, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Nicholas J. Vogelzang
Publikováno v:
Clinical genitourinary cancer. 18(6)
The open-label, phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab monotherapy 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma (RCC). Thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed41ec63369ca702699a2d70a008c2ee
https://pubmed.ncbi.nlm.nih.gov/32641261
https://pubmed.ncbi.nlm.nih.gov/32641261
Autor:
Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J George, Thomas Hutson, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e003844
BackgroundCheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac17dff67cac2f70defe6507bc19cad8
https://doi.org/10.1136/jitc-2021-003844
https://doi.org/10.1136/jitc-2021-003844
Autor:
Heidi Ann McKean, Joshua Zhang, Daniel J. George, Scott S. Tykodi, Jennifer L. Johansen, Jeffrey Yorio, Sunil Babu, Bradley Curtis Carthon, Michael R. Harrison, Jesus Zoco, Thomas E. Hutson, Ivor John Percent
Publikováno v:
Journal of Clinical Oncology. 39:315-315
315 Background: Combination therapy with nivolumab + ipilimumab (NIVO+IPI) has demonstrated long-term efficacy and tolerability for patients (pts) with previously untreated advanced renal cell carcinoma (aRCC). Most pivotal clinical trials in pts wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9394f486b0781c67bb5f8963da70d9c4
https://doi.org/10.1200/jco.2021.39.6_suppl.315
https://doi.org/10.1200/jco.2021.39.6_suppl.315
Autor:
Daniel J. George, Robert S. Alter, Rakesh Singal, Peter J. Van Veldhuizen, Ivor John Percent, Michael R. Harrison, Joshua Zhang, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Jennifer L. Johansen, Edward Arrowsmith, Scott S. Tykodi, Jesus Zoco, Thomas E. Hutson
Publikováno v:
Journal of Clinical Oncology. 39:309-309
309 Background: The long-term efficacy and tolerability of nivolumab (NIVO) 3 mg/kg + ipilimumab (IPI) 1 mg/kg Q3W × 4 doses followed by NIVO 3 mg/kg Q2W for previously untreated advanced RCC (aRCC) demonstrated in the registrational CheckMate 214 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0ba8c0349b36baf247a61e471a987c1
https://doi.org/10.1200/jco.2021.39.6_suppl.309
https://doi.org/10.1200/jco.2021.39.6_suppl.309
Autor:
Thomas Powles, Sumati Rao, Meredith M. Regan, Kyna Gooden, Jennifer L. Johansen, David F. McDermott, Michael B. Atkins, Charlene Mantia, Shuo Yang, Lillian Werner
Publikováno v:
Annals of Oncology. 30:v393-v394
Background Conventional measures such as median progression-free survival may suboptimally characterize the full impact of immuno-oncology (I-O) agents vs other systemic anticancer therapies. Patients discontinuing I-O agents may experience periods o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ae1183bb110a3be148c592184f769d9
https://doi.org/10.1093/annonc/mdz249.067
https://doi.org/10.1093/annonc/mdz249.067